CoChat

Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single‐dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs

Lankisch, M. R., Ferlinz, K. C., Leahy, J. L., Scherbaum, W. A., Orals Plus Apidra and LANTUS (OPAL) study group · 2008 · Diabetes, Obesity and Metabolism
Cited by 133

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Aim: To investigate whether the addition of a single bolus of insulin glulisine (glulisine), administered at either breakfast or main mealtime, in combination with basal insulin glargine (glargine) and oral antidiabetic drugs (OADs), provides equivalent glycaemic control in patients with type 2 diabetes, irrespective of the time of glulisine injection. Methods: A national, multicentre, randomized, open‐label, parallel‐group study of 393 patients with type 2 diabetes who were suboptimally controlled [haemoglobin A 1c (HbA 1c ) > 6.5–9.0% and fasting blood glucose (BG) ≤6.7 mmol/l] on their previous glargine and OAD regimen. A single injection of glulisine was added, either at breakfast or at main mealtime, to their existing therapy. Results: The per‐protocol group (n = 316) showed improved HbA 1c (baseline vs. end‐point) in the breakfast (7.4 vs. 7.0%; p < 0.0001) and main mealtime groups (7.3 vs. 6.9%; p < 0.0001). Glulisine given at breakfast was equally effective in controlling HbA 1c as glulisine given at the main mealtime [adjusted HbA 1c mean difference (95% confidence interval): 0.0481% (–0.115 to 0.211); p < 0.0001 for equivalence]. Overall, 30.7% of patients achieved HbA 1c ≤6.5% at end‐point but slightly more patients met this target in the main mealtime group vs. the breakfast group (33.8 vs. 27.8%; p = NS). This trend continued and was more marked when considering only those patients with HbA 1c >7.0% at baseline and who reached HbA 1c ≤7.0% at end‐point (44.1% overall), with 52.2 and 36.5% for main mealtime and breakfast groups, respectively (p = 0.028). Most postprandial BG values improved within each group, while the number of hypoglycaemias was low and comparable between the two treatment groups. Conclusions: A single bolus of glulisine, added to glargine and OADs, resulted in significantly improved HbA 1c levels, irrespective of whether glulisine was administered at breakfast or at main mealtime. These results may represent a simplified and effective approach to treatment intensification in type 2 diabetes patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2008.00967.x

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 133

Metadata

Authors
Lankisch, M. R., Ferlinz, K. C., Leahy, J. L., Scherbaum, W. A., & Orals Plus Apidra and LANTUS (OPAL) study group
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2008-10-29
Volume
10
Issue
12
Pages
1178-1185
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2060812966
Cited by
133
References
5
FWCI
8.06
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single‐dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. https://app.cochat.ai/papers/10.1111/j.1463-1326.2008.00967.x
The paper
Lankisch, M. R., Ferlinz, K. C., Leahy, J. L., Scherbaum, W. A., & Orals Plus Apidra and LANTUS (OPAL) study group. (2008). Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single‐dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2008.00967.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.